Auxilium Pharmaceuticals promotes James Tursi

Becomes chief medical officer having worked for US firm since 2009

Auxilium Pharmaceuticals, a US specialist biopharmaceutical company, has promoted James Tursi to chief medical officer. He has worked for Auxilium since March 2009 and has been responsible for the oversight of clinical development, clinical operations, biometrics and medical writing.

Tursi entered the pharmaceutical industry in 2004 as a medical director for Procter and Gamble Pharmaceuticals. He worked on several products and therapeutic areas, including female sexual dysfunction, overactive bladder, and osteoporosis. His responsibilities included clinical development and medical affairs. He moved to GlaxoSmithKline Biologicals in 2006 and directed all Medical Affairs responsibilities for cancer vaccines in North America.

You may also like

Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Regulatory

Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval

The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
Research & Development

Transmission Raman Spectroscopy - access the webinar series today

Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
Subscribe now